**Figure 30.**

*A—Ambulatory glucose profile (AGP) on multiple-dose injection regiment (MDI) with real-time glucose monitoring. B—Ambulatory glucose profile (AGP) after 6 months of sensor-augmented pump therapy with a hybrid close loop system (Control-IQ ™; t:slim X2™).*

and insulin dose correction, it fails to keep glycaemia within the recommended range. Real-time continuous glycaemic monitoring system (rtCGM) on the other hand improves the metabolic outcomes regardless of insulin delivery method [31]. Sensor-augmented pump therapy (SAP) integrates these two technologies into one functional system. In the course of the last few years, it has been further improved by a mathematical algorithm that allows semi-autonomous adjustments of subcutaneous insulin infusion according to the current glycaemia (hybrid close loop system—HCL). For the last 2 years, we have been using the Minimed™ 780G system (Medtronic) with the SmartGuard™ and also t:slim X2™ (Tandem) with the Control-IQ™. Those systems have been certified and fully approved for the treatment of T1DM in the Czech Republic. Our experience with the HCL system shows that it is possible to achieve very good results, surprisingly not only in well-cooperating and trained PWD1. **Figure 30** shows the increase of the TIR (Time In Range) and the enormous improvement of daily glucose pattern in a woman, who has been using Control-IQ hybrid close loop function of t:slim X2 inuslin pump for 6 months.
